The nation of Zimbabwe has declined a major US healthcare agreement valued at 367 million US dollars (272 million pounds) spanning five years because of the United States' insistence on sensitive biological samples.
This rejection was revealed following a official document dated December was leaked, indicating that President Emmerson Mnangagwa believed the arrangement was "unbalanced".
An official representative has since clarified that the US was requesting genetic material for research and profit but was not willing to guarantee the resulting advantages from any future medical innovations.
"We must now begin the difficult and regrettable process of winding down our health assistance in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the US had furnished over $1.9bn in health funding to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged more negotiations to find a deal suitable to both sides so the nation's vital HIV programme can continue.
Broader Context
Zimbabwe's decision follows a similar case in Kenya, where a court blocked a related deal with the US after concerns were raised about the security of Kenyans' medical information.
After returning to the presidency recently, US President Donald Trump has drastically cut foreign aid and closed the US Agency for International Development (USAID).
The agency had managed aid for the American government, but Trump claimed its expenditure was "inefficient" and his administration was pursuing direct bilateral agreements to enhance transparency and responsibility.
Based on reports, 16 nations in Africa have to date agreed to similar health pacts, representing over $18.3bn in new funding.
Specifics of the Declined Deal
This assistance for Zimbabwe would have gone towards "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this partnership would have delivered extraordinary advantages for Zimbabwean communities, particularly the 1.2 million presently receiving HIV treatment through US-supported programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the arrangement was "unfair".
"Our nation was requested to provide its biological resources and data indefinitely, without any equivalent guarantee of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could be developed from that provided information," Mangwana explained.
"Put simply, our country would provide the raw materials for medical research without any certainty that the resulting innovations would be available to our population if a future disease outbreak emerge."
National Interest and Global Health
He also said that the American exit from the global health body and its push of one-on-one health agreements were disrupting systems already set up via the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing system created to deal with future pandemics.
"This mechanism is designed to ensure that when a nation provides its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised solely by those with the resources to develop them."
These objections regarding the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome ongoing dialogue with our American counterparts on how future co-operation might be structured in a manner that respects the independence and dignity of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it understood the official position, but urged that negotiations need to persist given that much of the country's Aids initiatives relied on external financing.
"In cases where technical issues exist, such as those relating to data governance or implementation frameworks, these can often be resolved through technical clarification and negotiated safeguards," the group added.
The situation emphasises the continuing tensions between receiving crucial international aid and protecting local interests in an increasingly data-driven world.